Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | GGT1 | P19440 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13884310 | 0.84 | FOLH1 (0.40) | FOLH1POLBNOD1ITGB3ITGA2B | |
| SCHEMBL22803421 | 0.84 | POLB (0.35) | FOLH1POLB | |
| SCHEMBL26743889 | 0.81 | FOLH1 (0.43) | FOLH1NOD1TLR2GGT1 | |
| SCHEMBL14509613 | 0.80 | FOLH1 (0.37) | FOLH1POLBITGB3ITGA2B | |
| SCHEMBL19788645 | 0.80 | FOLH1 (0.47) | FOLH1ITGB3ITGA2B | |
| SCHEMBL24225804 | 0.79 | FOLH1 (0.42) | FOLH1NOD1GGT1 | |
| SCHEMBL18253629 | 0.78 | FOLH1 (0.68) | FOLH1 | |
| SCHEMBL24993609 | 0.78 | FOLH1 (0.43) | FOLH1NOD1TLR2 | |
| SCHEMBL9912229 | 0.78 | FOLH1 (0.68) | FOLH1 | |
| SCHEMBL24123152 | 0.78 | FOLH1 (0.68) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | FOLH1 64/4885POLB 1148/4885NOD1 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.